vs
ANI PHARMACEUTICALS INC（ANIP）とCSW INDUSTRIALS, INC.（CSW）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $233.0M、CSW INDUSTRIALS, INC.の約1.1倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 4.4%、差は6.7%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 20.3%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $22.7M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 5.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ANIP vs CSW — 直接比較
売上が大きい
ANIP
1.1倍大きい
$233.0M
売上成長率が高い
ANIP
+9.3%の差
20.3%
純利益率が高い
ANIP
純利益率が6.7%高い
4.4%
フリーキャッシュフローが多い
ANIP
FCF $6.4M多い
$22.7M
2年売上CAGRが高い
ANIP
2年複合成長率
5.1%
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $233.0M |
| 純利益 | $27.5M | $10.3M |
| 粗利率 | — | 39.7% |
| 営業利益率 | 14.1% | 7.4% |
| 純利益率 | 11.1% | 4.4% |
| 売上前年比 | 29.6% | 20.3% |
| 純利益前年比 | 367.5% | -61.9% |
| EPS（希薄化後） | $1.14 | $0.62 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ANIPCSW
| Q4 25 | $247.1M | $233.0M | ||
| Q3 25 | $227.8M | $277.0M | ||
| Q2 25 | $211.4M | $263.6M | ||
| Q1 25 | $197.1M | $230.5M | ||
| Q4 24 | $190.6M | $193.6M | ||
| Q3 24 | $148.3M | $227.9M | ||
| Q2 24 | $138.0M | $226.2M | ||
| Q1 24 | $137.4M | $210.9M |
純利益ANIPCSW
| Q4 25 | $27.5M | $10.3M | ||
| Q3 25 | $26.6M | $40.7M | ||
| Q2 25 | $8.5M | $40.9M | ||
| Q1 25 | $15.7M | $35.1M | ||
| Q4 24 | $-10.3M | $26.9M | ||
| Q3 24 | $-24.2M | $36.1M | ||
| Q2 24 | $-2.3M | $38.6M | ||
| Q1 24 | $18.2M | $31.8M |
粗利率ANIPCSW
| Q4 25 | — | 39.7% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 43.8% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | — | 41.4% | ||
| Q3 24 | — | 45.6% | ||
| Q2 24 | — | 47.5% | ||
| Q1 24 | — | 44.4% |
営業利益率ANIPCSW
| Q4 25 | 14.1% | 7.4% | ||
| Q3 25 | 15.9% | 20.5% | ||
| Q2 25 | 6.6% | 20.8% | ||
| Q1 25 | 13.3% | 19.5% | ||
| Q4 24 | -2.3% | 15.3% | ||
| Q3 24 | -13.8% | 22.6% | ||
| Q2 24 | 3.7% | 24.3% | ||
| Q1 24 | 14.8% | 21.0% |
純利益率ANIPCSW
| Q4 25 | 11.1% | 4.4% | ||
| Q3 25 | 11.7% | 14.7% | ||
| Q2 25 | 4.0% | 15.5% | ||
| Q1 25 | 8.0% | 15.2% | ||
| Q4 24 | -5.4% | 13.9% | ||
| Q3 24 | -16.3% | 15.8% | ||
| Q2 24 | -1.7% | 17.1% | ||
| Q1 24 | 13.2% | 15.1% |
EPS（希薄化後）ANIPCSW
| Q4 25 | $1.14 | $0.62 | ||
| Q3 25 | $1.13 | $2.41 | ||
| Q2 25 | $0.36 | $2.43 | ||
| Q1 25 | $0.69 | $2.05 | ||
| Q4 24 | $-0.45 | $1.60 | ||
| Q3 24 | $-1.27 | $2.26 | ||
| Q2 24 | $-0.14 | $2.47 | ||
| Q1 24 | $0.82 | $2.03 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $40.2M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $1.1B |
| 総資産 | $1.4B | $2.3B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資ANIPCSW
| Q4 25 | $285.6M | $40.2M | ||
| Q3 25 | $262.6M | $31.5M | ||
| Q2 25 | $217.8M | $38.0M | ||
| Q1 25 | $149.8M | $225.8M | ||
| Q4 24 | $144.9M | $213.8M | ||
| Q3 24 | $145.0M | $273.2M | ||
| Q2 24 | $240.1M | $18.9M | ||
| Q1 24 | $228.6M | $22.2M |
総負債ANIPCSW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $166.0M |
株主資本ANIPCSW
| Q4 25 | $540.7M | $1.1B | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.0B | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $650.2M | ||
| Q1 24 | $452.0M | $615.7M |
総資産ANIPCSW
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.0B |
負債/資本比率ANIPCSW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.27× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $28.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $22.7M |
| FCFマージンFCF / 売上 | 11.8% | 9.8% |
| 設備投資強度設備投資 / 売上 | 0.5% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.81× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $162.0M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローANIPCSW
| Q4 25 | $30.4M | $28.9M | ||
| Q3 25 | $44.1M | $61.8M | ||
| Q2 25 | $75.8M | $60.6M | ||
| Q1 25 | $35.0M | $27.3M | ||
| Q4 24 | $15.9M | $11.6M | ||
| Q3 24 | $12.5M | $66.8M | ||
| Q2 24 | $17.4M | $62.7M | ||
| Q1 24 | $18.3M | $22.4M |
フリーキャッシュフローANIPCSW
| Q4 25 | $29.1M | $22.7M | ||
| Q3 25 | $38.0M | $58.7M | ||
| Q2 25 | $71.8M | $57.7M | ||
| Q1 25 | $32.5M | $22.8M | ||
| Q4 24 | $13.5M | $8.5M | ||
| Q3 24 | $7.7M | $61.3M | ||
| Q2 24 | $13.0M | $59.6M | ||
| Q1 24 | $13.7M | $17.5M |
FCFマージンANIPCSW
| Q4 25 | 11.8% | 9.8% | ||
| Q3 25 | 16.7% | 21.2% | ||
| Q2 25 | 34.0% | 21.9% | ||
| Q1 25 | 16.5% | 9.9% | ||
| Q4 24 | 7.1% | 4.4% | ||
| Q3 24 | 5.2% | 26.9% | ||
| Q2 24 | 9.4% | 26.3% | ||
| Q1 24 | 10.0% | 8.3% |
設備投資強度ANIPCSW
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 2.0% | ||
| Q4 24 | 1.3% | 1.6% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 3.3% | 2.3% |
キャッシュ転換率ANIPCSW
| Q4 25 | 1.10× | 2.81× | ||
| Q3 25 | 1.66× | 1.52× | ||
| Q2 25 | 8.87× | 1.48× | ||
| Q1 25 | 2.23× | 0.78× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | 1.00× | 0.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
